BresaGen, Cythera complete merger
09 July, 2004 by Melissa TrudingerThe merger between Bresagen's US subsidiary Bresagen Inc and San Diego stem cell company Cythera has been completed.
WA researchers reveal smoke's 'phoenix factor'
09 July, 2004 by Graeme O'NeillEarly Australian settlers evocatively dubbed fire 'the red steer' -- the untamed beast that rampaged through the bush, grazing it back to bare earth. 'Red prince' might have been more appropriate, because the smoke from bushfires delivers a potent chemical kiss that rouses the sleeping seeds of many native plants -- including many of Australia's most beauteous species -- to vibrant life.
Biotech beats the All Ords, but market indigestion on the way
08 July, 2004 by Melissa TrudingerAustralia's biotechnology industry has had its best performing year since the halcyon days of the 1999-2000 tech boom, with both Intersuisse and Southern Cross Equities reporting a 24 per cent rise in their biotechnology indices to the end of the financial year, compared to the 18 per cent rise seen in the ASX's All Ordinaries Index.
CSIRO animal lab earns global recognition
07 July, 2004 by Graeme O'NeillCSIRO's Australian Animal Health Laboratory has been recognised for its work in identifying and managing new animal viruses that have caused the odd cold sweat in the corridors of human health agencies.
Epitan resumes sustained release trial
06 July, 2004 by Renate KrelleMelbourne-based EpiTan (ASX:EPT) has resumed its trial of the sustained release implant for tanning drug, Melanotan.
Metabolic caught off guard by share spike
06 July, 2004 by Melissa TrudingerMetabolic Pharmaceuticals was caught off guard yesterday when news of a favourable research report from US analysts Cohen Independent Research Group sent the company's shares up 65 per cent to close at AUD$1.65 after heavy trading.
Peptech profit tips $29.5 million
06 July, 2004 by Melissa TrudingerPeptech (ASX: PTD) has posted a net profit of AUD$29.5 million for the six months ending on 31 March 2004, mostly due to a hefty one-off settlement payment with Abbott and the first in a series of annual payments made under the settlement agreement.
Benitec licenses RNAi to Merck
05 July, 2004 by Melissa TrudingerBrisbane-based Benitec (ASX: BLT) has granted a non-exclusive research licence to Merck & Co, giving permission for Merck to use its DNA-directed RNAi (ddRNAi) technology in research activities.
Cytokine key to smallpox infection
02 July, 2004 by Staff WritersScientists at the Australian National University (ANU) have identified the immune response that determines why some mice are infected with mousepox and others are not, a discovery that could lead to better protection for humans in a bio-terror attack.
Norwood Immunology lists in UK at a premium
02 July, 2004 by Renate KrelleNorwood Immunology (AIM:NIM) commenced trading yesterday on London's Alternative Investment Market (AIM), with shares closing at 40.5 pence (AUD$1.046), a premium to their issue price of 38 pence.
Biotechs gear up for new 'best practice' rules
02 July, 2004 by Melissa TrudingerIn this financial year's upcoming crop of annual reports, ASX-listed companies will have to include a section disclosing their adherence to the 10 essential corporate governance principles developed in 2002 by the exchange's corporate governance council as a framework for best practice.
Ventracor, Agenix grab grants
01 July, 2004 by Renate KrelleSydney artificial heart company Ventracor (ASX:VCR) scooped up AUD$1.2 million in funding today, when the second round of Australian Research Council (ARC) linkage grants were announced.
Blue day as Florigene and Suntory unveil a biotech holy grail
01 July, 2004 by Melissa TrudingerIt has taken 15 years, but Australian company Florigene and its Japanese parent Suntory say they have succeeded in creating the holy grail of floristry -- the blue rose.
Amrad halts buyback during Avexa spin-out
01 July, 2004 by Melissa TrudingerAmrad (ASX:AML) has halted its share buy-back program while it readies itself to spin out its anti-infectives program.
Stirling products to test growth promotors in sheep.
30 June, 2004 by Renate KrellePerth-based Stirling Products (ASX:STI) is preparing for the first animal trials of its ST810 growth promotion agent in sheep.
